Written and maintained by CASRAI Editorial Board
Last updated
Quick answer: if the drug you want to study is already lawfully marketed in the United States, your study is exempt from IND requirements only if it clears all four gates of 21 CFR 312.2(b)(1) at once — no new indication or significant labeling/advertising change, no significant increase in risk, compliant IRB review and informed consent, and no promotional intent. Fail even one, and you need a full IND, most often filed as a research (Investigator) IND for a university-led study. This guide walks the decision itself first, then what follows once you know the answer.
The decision tree: do you need an IND?
Work through these four gates in order. Under 21 CFR 312.2(b)(1), a clinical investigation of a drug product already lawfully marketed in the United States is exempt from IND requirements only if every gate below is cleared — the test is conjunctive, not a majority vote. Source: 21 CFR 312.2(b), verified against the current eCFR text.
Gate 1 — Is the drug already lawfully marketed in the United States?
If the answer is no — you are studying an unapproved drug, a new chemical entity, or an approved drug’s active ingredient in a novel formulation FDA has not cleared — the 312.2(b) exemption does not apply at all, regardless of how the rest of the study is designed. Stop here: you need a full IND. If yes, continue to Gate 2.
Gate 2 — Will the study be used to support a new indication, or any other significant change in labeling, or (for a prescription drug) a significant change in advertising?
Per 312.2(b)(1)(i)–(ii), the investigation cannot be intended for reporting to FDA as a well-controlled study in support of a new indication, nor to support any other significant labeling change, nor — for a prescription drug — a significant advertising change. A study designed to generate the evidence for a future label expansion fails this gate even if the clinical conduct looks low-risk. If the intent is there, you need a full IND. If not, continue.
Gate 3 — Does the study involve a route, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) relative to the drug’s approved use?
This is 312.2(b)(1)(iii), and it is the gate most IIT teams get wrong, because “significantly increases risk” is not defined by a bright-line threshold in the regulation — it requires a substantive judgment call relative to the approved labeling, known adverse-event profile, and how far the proposed dose, route, or population departs from it. A higher dose, an unapproved route, a vulnerable population (pediatric, pregnant, cognitively impaired) not covered by the approved label, or a longer duration of exposure are the recurring triggers. If risk is significantly increased, you need a full IND — typically a research IND. If not, continue.
Gate 4 — Will the study run under an IRB compliant with 21 CFR Part 56, obtain informed consent compliant with 21 CFR Part 50, and comply with the no-promotion rule of 21 CFR 312.7?
Per 312.2(b)(1)(iv)–(v), the exemption also requires the study to be conducted under compliant institutional review and informed consent, and not be used to promote or commercialize the drug for an unapproved use. Almost every university-run study already clears this gate through normal IRB process — it is rarely the failure point, but it is a real, independent condition, not a formality.
Clear all four gates and the study is exempt from IND requirements under 312.2(b). Miss any one, and a full IND is required before you can enroll a single subject. Because the determination sits with the sponsor rather than requiring FDA pre-clearance, document the gate-by-gate reasoning in the protocol or IRB submission — FDA can and does challenge an exemption claim after the fact on inspection, and there is no case-by-case advance sign-off to fall back on. See CASRAI’s IND Exemption (21 CFR 312.2(b)) entry for the underlying definition and worked examples.
Worked investigator-initiated-trial scenarios
The following are illustrative composites built to demonstrate how the gates apply — they are not real studies, institutions, or investigators.
- Scenario A — exempt. A university cardiologist wants to compare two FDA-approved antihypertensive drugs, each dosed and administered strictly within its approved label, in a general adult population, purely to inform local prescribing practice. No new indication is sought, risk is unchanged from approved use, and the study runs under normal IRB review and informed consent. This clears all four gates — no IND needed.
- Scenario B — needs an IND. A university oncologist wants to study an FDA-approved chemotherapy drug at a substantially higher dose than its approved labeling, for a cancer type it is not approved to treat. This fails Gate 2 (new indication) and Gate 3 (dose that significantly increases risk) simultaneously — a full IND, most likely a research IND held by the investigator as sponsor-investigator, is required even though the drug itself is already FDA-approved for a different use.
- Scenario C — needs an IND despite looking low-risk. A hospital pharmacy department wants to study an approved oral antibiotic at its approved dose and route, but the results are explicitly intended to support a future labeling supplement and accompanying advertising claims. Clinically the study looks exemption-eligible, but the stated intent independently fails Gate 2 — a full IND is required.
Narrower statutory exemptions worth knowing
Beyond the 312.2(b)(1) four-gate test above, 21 CFR 312.2(b) separately exempts a short list of narrower categories: certain in vitro diagnostic biological products including blood grouping serum, reagent red blood cells, and anti-human globulin (312.2(b)(2)); a drug intended solely for in vitro tests or laboratory research animals, if shipped per 21 CFR 312.160 (312.2(b)(3)); and, generally, a clinical investigation involving use of a placebo, if the investigation does not otherwise require an IND (312.2(b)(5)). One exception runs the other direction: a study relying on the exception from informed consent for emergency research under 21 CFR 50.24 is not exempt from IND requirements (312.2(b)(6)), even though it touches the same Part 50 framework Gate 4 references above. FDA will not accept an IND application for a study that is exempt under 312.2(b)(1) in the first place (312.2(b)(4)).
FDA’s own guidance document for this exact question — Investigational New Drug Applications (INDs) — Determining Whether Human Research Studies Can Be Conducted Without an IND (issued September 2013, for clinical investigators, sponsors, sponsor-investigators, and IRBs) — walks through the same 312.2(b) analysis in narrative form and specifically addresses situations FDA has found are a recurring source of confusion. It is worth reading in full for a borderline determination; this page distills the regulatory test into a decision sequence, it does not replace individualized regulatory judgment on a genuinely close call.
If you need an IND: which type?
| IND type | Who typically files it | When it applies |
|---|---|---|
| Commercial IND | A pharmaceutical or biotech company, as sponsor | Standard development-stage IND supporting an eventual marketing application. |
| Research (Investigator) IND | An individual physician who both initiates and conducts the study — the sponsor-investigator | The common structure for academic, investigator-initiated trials studying a new use, dose, combination, or population for an already-marketed drug. |
| Emergency Use IND | A physician (or company) seeking authorization to use an investigational drug in a genuine life-threatening emergency, without time to file a standard IND | A single named patient, true emergency, no time for the normal IND process. |
| Treatment IND / expanded access | Sponsor of an existing IND, or a physician on a patient’s behalf | Provides investigational drug access to patients outside a formal trial who have a serious condition and no comparable alternative — see CASRAI’s Compassionate Use / Expanded Access guide for the full framework. |
For most university IIT teams that clear the gate test negatively (i.e., need an IND), the research/Investigator IND is the relevant structure — the same individual who designed the study also becomes its regulatory sponsor.
What the submission has to contain, and the 30-day clock
An IND is an assembled package, not a single form: per 21 CFR 312.23(a) it includes the Form FDA 1571 cover sheet, an introductory statement and general investigational plan, the investigator’s brochure (or its investigator-IND equivalent), the clinical protocol, chemistry/manufacturing/controls (CMC) data, pharmacology and toxicology data, and prior human experience. Once filed, FDA has 30 calendar days to place the study on clinical hold under 21 CFR 312.42; absent a hold, the IND goes into effect automatically. CASRAI’s Filing an IND: Application to 30-Day Clock guide covers this full mechanical process end to end, and the Form 1571 and Form 1572 guides cover the two most commonly mishandled forms field by field. The investigator’s-brochure requirement itself is covered in CASRAI’s Investigator Brochure: Contents and Updates guide, and, for a novel product, the nonclinical package generally needs to include IND-enabling studies.
Taking an IND makes you the sponsor — obligations most academics underestimate
This is the point that catches IIT teams off guard most often: filing a research IND does not just add a form to an investigator’s existing role. Under 21 CFR 312.3, a sponsor-investigator is a single individual (never an institution) who both initiates and conducts the study — and that individual takes on the full set of sponsor responsibilities in Subpart D in addition to the full set of investigator responsibilities, with no reduced or merged obligation for holding both roles at once.
| Sponsor duties (312.50–312.59) | Investigator duties (312.60–312.70) |
|---|---|
| General sponsor responsibilities (312.50); selecting qualified investigators and monitors (312.53); informing investigators of new safety information (312.55); reviewing ongoing investigations for safety (312.56); sponsor recordkeeping and record retention (312.57); disposition of unused drug supply (312.59) | General investigator responsibilities including adherence to the protocol (312.60); control of the investigational drug supply (312.61); investigator recordkeeping (312.62); investigator reports, including safety findings (312.64); assurance of IRB review (312.66) |
In practice, that means the sponsor-investigator personally carries: expedited IND Safety Reports under 21 CFR 312.32 for unexpected fatal or life-threatening events and other qualifying findings; a required IND Annual Report summarizing the year’s progress for as long as the IND remains active; drug accountability and control records; a Delegation of Authority (DoA) log and the site’s own Form FDA 1572 obligations if other sites or sub-investigators participate; monitoring the study for safety on an ongoing basis (312.56) rather than relying solely on a separate sponsor to do it; and, for a registered trial, the ClinicalTrials.gov responsible-party role under FDAAA 801, which attaches to the individual sponsor-investigator personally, including civil-penalty exposure, even where the institution’s research office handles the actual PRS submission mechanics.
None of this is optional or delegable away in substance — it can be operationally supported by a regulatory affairs office, a clinical trials unit, or a contract research organization under a written transfer-of-obligations arrangement (21 CFR 312.52), but the regulatory accountability for a research IND sits with the named individual sponsor-investigator, not the university as an institution. That is the single biggest resourcing gap institutions underestimate when a faculty member’s study crosses from “IND-exempt” to “needs a research IND.”
The research-administration angle: who signs, what the IRB needs, and how to resource it
- Who signs Form FDA 1571. For a research IND, the sponsor-investigator signs as sponsor — not a university official, since 21 CFR 312.3 restricts the sponsor-investigator role to an individual. Institutions cannot hold the IND on the investigator’s behalf; they can only support the individual who does.
- What the IRB needs, exemption or not. Reaching an IND exemption under 312.2(b) does not remove the requirement for IRB review and informed consent — Gate 4 above is itself an IRB/consent condition. Route the gate-by-gate 312.2(b) analysis through the IRB or research-compliance office as part of protocol review either way, so the reasoning is documented before enrollment, not reconstructed after an inspection finding.
- Resourcing a research IND before it’s filed. Budget for pre-IND regulatory-affairs support (often via a sponsor-investigator‘s home institution or a clinical trials office), ongoing safety-monitoring capacity to meet the 312.56/312.32 obligations above, annual-report preparation, and drug-accountability administration for the life of the IND — not just the cost of the pre-IND meeting and initial filing. A Pre-IND Meeting (see also CASRAI’s FDA meeting types guide) is a low-cost way to surface whether FDA agrees a planned study needs a full IND, or whether a design change could keep it within the 312.2(b) exemption, before those ongoing obligations are locked in.
- Where this sits relative to the rest of the trial lifecycle. The IND decision runs in parallel with, but independently of, the IRB approval process (see CASRAI’s IRB/REC approval process guide) and the broader clinical trial phases framework the study will proceed through once cleared.
Frequently Asked Questions
Do I need an IND for my study?
Only if the drug is not already lawfully marketed in the US, or the study fails any one of the four 312.2(b) gates: no new indication/labeling or advertising change, no significant increase in risk, and compliant IRB review, informed consent, and no promotional intent. Clearing all four gates means the study is exempt; failing any one means a full IND is required. Walk the decision tree above in order.
What is an IND exemption?
A 21 CFR 312.2(b) IND exemption is the regulatory determination — made by the sponsor, not pre-cleared by FDA — that a study of an already-marketed drug can proceed without an IND application because it meets all five conditions the rule sets out. See CASRAI’s IND Exemption entry for the full definition and worked examples.
What’s the difference between a research (Investigator) IND and a commercial IND?
Both follow the same 312.23(a) content requirements, but a research IND is filed by an individual sponsor-investigator who both designs and conducts the study, most often for a new use, dose, combination, or population of an already-marketed drug — the common structure for university investigator-initiated trials. A commercial IND is filed by a company as sponsor, typically for a novel compound heading toward a marketing application.
Does an IND exemption remove the need for IRB approval?
No. Compliant IRB review under 21 CFR Part 56 and informed consent under 21 CFR Part 50 are themselves one of the four gates the exemption requires (312.2(b)(1)(iv)) — an exempt study still goes through normal IRB review; it simply does not also need an IND.
What happens if I claim the exemption incorrectly?
Enrolling subjects without an IND when one was actually required exposes the sponsor and institution to a clinical hold, required corrective action, and potential regulatory findings on inspection — there is no case-by-case FDA pre-clearance for an exemption claim, so the risk of getting the judgment call wrong sits entirely with the sponsor until and unless FDA reviews it.
Who is legally the sponsor if a university investigator holds a research IND?
The named individual sponsor-investigator personally — 21 CFR 312.3 defines sponsor-investigator as an individual only, and an institution cannot itself hold that role. The university can support the work operationally (regulatory affairs, safety monitoring, a clinical trials office) but the regulatory sponsor obligations under Subpart D attach to the individual.
How long does it take to get an IND into effect?
Once a complete IND is filed, FDA has up to 30 calendar days to place the study on clinical hold under 21 CFR 312.42; absent a hold, the IND goes into effect automatically at day 30, or earlier if FDA affirmatively authorizes the study sooner. That clock does not include the time needed to assemble the IND itself, or an optional pre-IND meeting beforehand — see CASRAI’s Filing an IND guide for the full sequence.
Last verified: August 21, 2026, directly against 21 CFR 312.2 (Subpart A, exemptions) via the eCFR current text, cross-checked against CASRAI’s existing sourced IND Exemption dictionary entry and FDA’s September 2013 guidance “Investigational New Drug Applications (INDs) — Determining Whether Human Research Studies Can Be Conducted Without an IND.” Regulatory text changes infrequently; re-check the current 21 CFR 312.2 text if reading this more than a year or two later.
See also: New Molecular Entity.
